Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

BLA accepted for obecabtagene autoleucel (obe-cel) as a potential treatment for R/R Adult B-cell ALL

January 31, 2024

Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant NSCLC

January 23, 2024

Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)

January 23, 2024

Submission of Complete Response to Clinical Hold for HEMO-CAR-T IND

January 23, 2024

FDA Accepts the PMA Application for TTFields Therapy in NSCLC

January 23, 2024

TIVDAK® sBLA Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer

January 17, 2024

Update on Zolbetuximab Biologics License Application in U.S.: FDA rejects the application

January 17, 2024

FDA Fast Track Designation for SLS009 for Treatment of R/R AML

January 17, 2024

ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate) announced

January 17, 2024

RC88 Obtained FDA Fast Track Designation

January 17, 2024

FDA Issued New Postmarketing Requirement on sNDA seeking full approval of LUMAKRAS® (sotorasib)

January 10, 2024

FDA Clears IND for SC262 for Patients with R/R B-cell Malignancies

January 10, 2024

U.S. FDA clears IND Enabling Ph 1 Initiation for OKI-219

January 10, 2024

Rinatabart Sesutecan FDA Fast Track Designation for Patients with Advanced Ovarian Cancer

January 10, 2024

U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program

January 10, 2024

FDA Clears IND Application for SENTI-202 for the Treatment of R/R Hematologic Malignancies Including AML

January 4, 2024

sBLA and NDA submitted for RYBREVANT® (amivantamab-vmjw) + Lazertinib for the Treatment of Patients with EGFR-Mutated NSCLC

January 4, 2024

U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer

January 4, 2024

EMA confirms recommendation for non-renewal of authorisation of multiple myeloma medicine Blenrep

January 4, 2024

FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer

January 4, 2024

Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated NSCLC

January 4, 2024

FDA guides on the next Ph 2 study for advancement of Next Generation Capecitabine (“NGC-Cap”) for cancer patients

December 19, 2023

Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma

December 19, 2023

FDA grants priority review for tarlatamab in SCLC

December 19, 2023

Application submitted to the EMA for RYBREVANT + Chemo for the Treatment of Adult Patients with Advanced EGFR-Mutated NSCLC After Failure of Prior Therapy

December 11, 2023
Page1 … Page19 Page20 Page21 Page22 Page23 … Page31

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.